Synopsis
Synopsis
0
CEP/COS
0
VMF
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Cp 690,550
2. Cp 690550
3. Cp-690,550
4. Cp-690550
5. Cp690550
6. Tasocitinib
7. Tofacitinib
8. Xeljanz
1. 540737-29-9
2. Tasocitinib Citrate
3. Xeljanz
4. Cp-690550 Citrate
5. Tofacitinib (citrate)
6. Tofacitinib (cp-690550) Citrate
7. Xeljanz Xr
8. Tofacitinib Citrate [usan]
9. Cp-690,550-10
10. Tasocitinib Monocitrate
11. 540737-29-9 (citrate)
12. Cp-690550-10
13. Cp 690550 Citrate
14. O1ff4div0d
15. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate
16. Chebi:71197
17. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)- Beta-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
18. 2-hydroxypropane-1,2,3-tricarboxylic Acid; 3-[(3r,4r)-4-methyl-3-[methyl({7h-pyrrolo[2,3-d]pyrimidin-4-yl})amino]piperidin-1-yl]-3-oxopropanenitrile
19. 2-hydroxypropane-1,2,3-tricarboxylic Acid;3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile
20. Unii-o1ff4div0d
21. Mfcd11616529
22. 3-{(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate
23. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Citrate Salt
24. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl}-amino]-piperidin-1-yl)-3-oxo-propionitrile Citrate Salt
25. Xeljanz (tn)
26. Tofacitinib Monocitrate
27. Tasocitinib Citric Acid Salt
28. Cep-18770(delanzomib)
29. Mls006010058
30. Schembl1374185
31. Chembl2103743
32. Tofacitinib Citrate (jan/usan)
33. Amy4175
34. Dtxsid80202404
35. Ex-a204
36. Tofacitinib Citrate [jan]
37. C16h20n6o.c6h8o7
38. Tofacitinib Monocitrate [mi]
39. Hy-40354a
40. S5001
41. Tofacitinib Citrate [who-dd]
42. Akos022178222
43. Cp-690550 - Tofacitinib Citrate
44. Tofacitinib Citrate, >=98% (hplc)
45. Ccg-269730
46. Cs-0928
47. Tofacitinib Citrate [orange Book]
48. Ac-25004
49. As-19392
50. Bt163661
51. Smr004701220
52. Cp-690550 Citrate (tofacitinib Citrate)
53. Tofacitinib Citrate (cp-690550 Citrate)
54. Cp 690550-10
55. D09783
56. Q27139435
57. (3r,4r)-4-methyl-3-(methyl-7h-pyrro Lo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepro Panenitrile Citrate
58. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-?-oxo-1-piperidinepropanenitrile Citrate
59. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidine Propanenitrile 2-hydroxy-1,2,3-propanetricarboxylate
60. (3r,4r)-4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-ss-oxo-1-piperidinepropanenitrile Citrate Salt
61. 1-piperidinepropanenitrile, 4-methyl-3-(methyl-7h-pyrrolo(2,3-d)pyrimidin-4-ylamino)-.beta.-oxo-, (3r,4r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)
62. 1-piperidinepropanenitrile,4-methyl-3-(methyl-7h-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-,(3r,4r)-,2-hydroxy-1,2,3-propanetricarboxylate(1:1)
63. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxo-propanenitrile2-hydroxypropane-1,2,3-tricarboxylate (1:1)
64. 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile Mono Citrate Salt
65. 3-{(3r,4r)-4-methyl-3-[methyl-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile Mono Citrate Salt
| Molecular Weight | 504.5 g/mol |
|---|---|
| Molecular Formula | C22H28N6O8 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 8 |
| Exact Mass | 504.19686187 g/mol |
| Monoisotopic Mass | 504.19686187 g/mol |
| Topological Polar Surface Area | 221 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 716 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Xeljanz |
| PubMed Health | Tofacitinib (By mouth) |
| Drug Classes | Antirheumatic, Musculoskeletal Agent |
| Drug Label | XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy... |
| Active Ingredient | Tofacitinib citrate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 5mg base |
| Market Status | Prescription |
| Company | Pf Prism Cv |
| 2 of 2 | |
|---|---|
| Drug Name | Xeljanz |
| PubMed Health | Tofacitinib (By mouth) |
| Drug Classes | Antirheumatic, Musculoskeletal Agent |
| Drug Label | XELJANZ is the citrate salt of tofacitinib, a JAK inhibitor.Tofacitinib citrate is a white to off-white powder with the following chemical name: (3R,4R)-4-methyl-3-(methyl-7H-pyrrolo [2,3-d]pyrimidin-4-ylamino)--oxo-1-piperidinepropanenitrile, 2-hy... |
| Active Ingredient | Tofacitinib citrate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | eq 5mg base |
| Market Status | Prescription |
| Company | Pf Prism Cv |
Janus Kinase Inhibitors
Agents that inhibit JANUS KINASES. (See all compounds classified as Janus Kinase Inhibitors.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Rheumatic Diseases.
Lead Product(s):
Methotrexate,Sulfasalazine,Hydroxychloroquine Sulphate,Leflunomide,Azathioprine,Mycophenolic Acid,Cyclosporine,Tacrolimus,
Therapeutic Area: Rheumatology
Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug Sponsor:
Undisclosed
Deal Size: Inapplicable
Upfront Cash: Inapplicable
Deal Type: Inapplicable
August 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) :
Methotrexate,Sulfasalazine,Hydroxychloroquine Sulphate,Leflunomide,Azathioprine,Mycophenolic Acid,Cyclosporine,Tacrolimus,
Therapeutic Area :
Rheumatology Highest Development Status :
Phase II Partner/Sponsor/Collaborator :
Undisclosed Deal Size : Inapplicable Deal Type : Inapplicable
Immunosuppressant Management in Rheumatology Patients Undergoing Shoulder Arthroplasty
Details : Methotrexate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Rheumatic Diseases.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 24, 2025

Details:
Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Tofacitinib Citrate,CGB-500
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 11, 2025

Lead Product(s) : Tofacitinib Citrate,CGB-500
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2025

Details:
Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Tofacitinib Citrate,CGB-500
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2025

Lead Product(s) : Tofacitinib Citrate,CGB-500
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tofacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The net proceeds will be used to fund the clinical development of its oral biotherapeutics platform, BT-600 (tofacitinib) for the treatment of Ulcerative Colitis.
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: H.C. Wainwright & Co
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 29, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Biora Therapeutics Prices $3M Direct Offering Under Nasdaq Rules
Details : The net proceeds will be used to fund the clinical development of its oral biotherapeutics platform, BT-600 (tofacitinib) for the treatment of Ulcerative Colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 29, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Announces Supplemental Data from Phase 1 Trial of BT-600
Details : BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Details : BT-600 (tofacitinib) is a drug-device combination program consisting of the orally administered NaviCap™ device which delivers tofacitinib to the colon for treatment of ulcerative colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Completes Multiple-Ascending Dose Cohorts for BT-600 Clinical Trial
Details : BT-600 (tofacitinib) is a drug-device combination using the NaviCap™ device to deliver a liquid formulation of tofacitinib to the colon, aimed at treating moderate to severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 30, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Biora Therapeutics Achieves Positive Interim Results for BT-600 in NaviCa Platform Trial
Details : BT-600 is a drug device combination containing liquid formulation of tofacitinib (JAK inhibitor). It is being evaluated for the treatment of ulcerative colitis
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: H.C. Wainwright & Co
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $6.0 million
Deal Type : Private Placement
Biora Therapeutics Closes $6 Million Registered Direct Offering Priced At-the-Market
Details : Biora intends to use the net proceeds from this offering to support its operations, complete its ongoing BT-600 (tofacitinib) clinical trial for the treatment of moderate to severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Biora intends to complete its clinical trial of BT-600, a drug-device combination delivering tofacitinib to the colon for treating moderate to severe ulcerative colitis.
Lead Product(s): Tofacitinib Citrate,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: H.C. Wainwright & Co
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 01, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tofacitinib Citrate,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : H.C. Wainwright & Co
Deal Size : $6.0 million
Deal Type : Public Offering
Biora Announces $6 Million Direct Offering Priced At-the-Market
Details : Biora intends to complete its clinical trial of BT-600, a drug-device combination delivering tofacitinib to the colon for treating moderate to severe ulcerative colitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 01, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]4-Chloro-7H-pyrrolo[2,3-d]pyrimidine
CAS Number : 3680-69-1
End Use API : Tofacitinib Citrate
About The Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With fa...
(3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidina...
CAS Number : 1062580-52-2
End Use API : Tofacitinib Citrate
About The Company : Established in 2004 and headquartered in Hangzhou, Hengkang established multiple factories, research and sales centers in Zhejiang, Shandong, and Henan. With fa...
4-Chloropyrrolo[2,3-d]pyrimidine
CAS Number : 3680-69-1
End Use API : Tofacitinib Citrate
About The Company : Aarti Pharmalabs is generic APIs & Intermediates manufacturing company & small molecule drug substance CDMO and the largest Indian manufacturer of Xanthine Deri...
(3R,4R)-N,4-Dimethyl-1 (phenylmethyl)-3-piperidina...
CAS Number : 1062580-52-2
End Use API : Tofacitinib Citrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
4-Chloro-7-[(4- methylphenyl)sulfonyl]-7H- pyrrolo...
CAS Number : 479633-63-1
End Use API : Tofacitinib Citrate
About The Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square mete...
(3R,4R)-N,4-Dimethyl-1-(phenylmethyl)-3-piperidina...
CAS Number : 1062580-52-2
End Use API : Tofacitinib Citrate
About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...
4-Chloro-5h-pyrrolo[3,2-d] Pyrimidine
CAS Number : 84905-80-6
End Use API : Tofacitinib Citrate
About The Company : Indian Drugs And Chemicals supplies quality products using modern technologies, supported by strong industry expertise. The company serves global markets with a...
4-Chloro-7H-pyrrolo-[2,3-d]pyrimidine
CAS Number : 3680-69-1
End Use API : Tofacitinib Citrate
About The Company : Allsino Pharmaceutical, established in May 2004, spans 97,350m² and specializes in the R&D and manufacturing of RSMs, GMP intermediates, and APIs. Our products...

5(N-methyl-N-((3S,4R)-4- methylpiperidin-3-yl)-7Hp...
CAS Number : CAS-477600-74-1
End Use API : Tofacitinib Citrate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

(3R,4R)-1-Benzyl-N,4- Dimethylpiperidin-3-Amine
CAS Number : CAS-477600-70-7
End Use API : Tofacitinib Citrate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Brand Name :
Dosage Form : Oral Solid Dosage Form
Dosage Strength : 22MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Lead Market Dossiers- Under Development
Registration Country : India
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : TOFACITINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 209633
Regulatory Info :
Registration Country : USA
Regulatory Info :
Registration Country : Iran
Brand Name : Rhofanib
Dosage Form : Film Coated Tablet
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Rhofanib
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
Brand Name : TOFACITINIB CITRATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2023-03-13
Application Number : 209738
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : XELJANZ
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2012-11-06
Application Number : 203214
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : XELJANZ
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Packaging :
Approval Date : 2018-05-30
Application Number : 203214
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : XELJANZ XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 11MG BASE
Packaging :
Approval Date : 2016-02-23
Application Number : 208246
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
Brand Name : XELJANZ XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 22MG BASE
Packaging :
Approval Date : 2019-12-12
Application Number : 208246
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : USA
Brand Name : TOFACITINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number : 209923
Regulatory Info :
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : TOFACITINIB
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date :
Application Number : 209633
RX/OTC/DISCN :
RLD :
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : TOFACITINIB CITRATE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 11MG BASE
Approval Date : 2025-08-19
Application Number : 219542
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : TOFACITINIB
Dosage Form : TABLET
Dosage Strength : 5MG
Approval Date :
Application Number : 215356
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : TOFACITINIB CITRATE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 11MG BASE
Approval Date :
Application Number : 219442
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : TOFACITINIB CITRATE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 22MG BASE
Approval Date :
Application Number : 219442
RX/OTC/DISCN :
RLD :
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : XELJANZ
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Approval Date : 2012-11-06
Application Number : 203214
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : XELJANZ
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Approval Date : 2018-05-30
Application Number : 203214
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : XELJANZ XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 11MG BASE
Approval Date : 2016-02-23
Application Number : 208246
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code :
Brand Name : XELJANZ XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 22MG BASE
Approval Date : 2019-12-12
Application Number : 208246
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD :
TE Code :
Brand Name : Tofacitinib
Dosage Form : TABLET;ORAL
Dosage Strength : 5MG
Approval Date :
Application Number : 215552
RX/OTC/DISCN :
RLD :
TE Code :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
81
PharmaCompass offers a list of Tofacitinib Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tofacitinib Citrate manufacturer or Tofacitinib Citrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tofacitinib Citrate manufacturer or Tofacitinib Citrate supplier.
PharmaCompass also assists you with knowing the Tofacitinib Citrate API Price utilized in the formulation of products. Tofacitinib Citrate API Price is not always fixed or binding as the Tofacitinib Citrate Price is obtained through a variety of data sources. The Tofacitinib Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CP 690550 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CP 690550, including repackagers and relabelers. The FDA regulates CP 690550 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CP 690550 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CP 690550 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CP 690550 supplier is an individual or a company that provides CP 690550 active pharmaceutical ingredient (API) or CP 690550 finished formulations upon request. The CP 690550 suppliers may include CP 690550 API manufacturers, exporters, distributors and traders.
click here to find a list of CP 690550 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CP 690550 DMF (Drug Master File) is a document detailing the whole manufacturing process of CP 690550 active pharmaceutical ingredient (API) in detail. Different forms of CP 690550 DMFs exist exist since differing nations have different regulations, such as CP 690550 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CP 690550 DMF submitted to regulatory agencies in the US is known as a USDMF. CP 690550 USDMF includes data on CP 690550's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CP 690550 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CP 690550 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CP 690550 Drug Master File in Japan (CP 690550 JDMF) empowers CP 690550 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CP 690550 JDMF during the approval evaluation for pharmaceutical products. At the time of CP 690550 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CP 690550 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a CP 690550 Drug Master File in Korea (CP 690550 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of CP 690550. The MFDS reviews the CP 690550 KDMF as part of the drug registration process and uses the information provided in the CP 690550 KDMF to evaluate the safety and efficacy of the drug.
After submitting a CP 690550 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their CP 690550 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of CP 690550 suppliers with KDMF on PharmaCompass.
A CP 690550 written confirmation (CP 690550 WC) is an official document issued by a regulatory agency to a CP 690550 manufacturer, verifying that the manufacturing facility of a CP 690550 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CP 690550 APIs or CP 690550 finished pharmaceutical products to another nation, regulatory agencies frequently require a CP 690550 WC (written confirmation) as part of the regulatory process.
click here to find a list of CP 690550 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CP 690550 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CP 690550 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CP 690550 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CP 690550 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CP 690550 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CP 690550 suppliers with NDC on PharmaCompass.
CP 690550 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CP 690550 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CP 690550 GMP manufacturer or CP 690550 GMP API supplier for your needs.
A CP 690550 CoA (Certificate of Analysis) is a formal document that attests to CP 690550's compliance with CP 690550 specifications and serves as a tool for batch-level quality control.
CP 690550 CoA mostly includes findings from lab analyses of a specific batch. For each CP 690550 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CP 690550 may be tested according to a variety of international standards, such as European Pharmacopoeia (CP 690550 EP), CP 690550 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CP 690550 USP).